GlaxoSmithKline PLC (LSE:GSK) - Share price


Stock Report

GlaxoSmithKline PLC GSK

Last Price
GBX1,595.20

Day Change
6.80|0.43%

As of 18/06/2019
18:45:04 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,588.40p
Day Range1,589.58 - 1,616.00
Mkt Cap79.23Bil
52-Wk Range1,408.80 - 1,648.80
Yield %5.02
ISINGB0009252882
Volume8,230,701
P/E15.93
P/S0.03
P/CF0.09

Share Price

Total Returns 17/06/2019

 Chg (%)  
More ...
GlaxoSmithKline PLC2.15 
FTSE 100 TR GBP0.39
 
Financials
201620172018
More ...
Income Statement
Turnover27,889.0030,186.0030,821.00
Operating Profit6,026.006,061.007,064.00
Net Profit1,062.002,169.004,046.00
Reported EPS18.6031.0072.90
Balance Sheet
Current Assets16,496.0015,794.0016,274.00
Non Current Assets42,370.0040,474.0041,139.00
Total Assets59,081.0056,381.0058,066.00
Current Liabilities19,001.0026,569.0022,491.00
Total Liabilities---
Total Equity4,963.003,489.003,672.00
Cash Flow
Operating Cash Flow8,106.008,258.009,747.00
Net Change in Cash-1,164.00-905.00479.00

Regulatory News

DateAuthor Headline
08/02/2019Damien Conover GlaxoSmithKline Still Undervalued, say Analysts
FTSE 100 pharmaceutical giant has reached an inflection point, argue Morningstar analysts, moving beyond ashthma drug Advair to HIV, vaccines and consumer healthcare
29/01/2019Emma Wall Top 20 FTSE 100 Dividend Paying Stocks
THE INCOME INVESTOR: The largest companies in the UK source their revenues internationally, meaning your dividend stream is boosted by global economic growth
21/01/2019Emma Wall 5 Quality UK Stocks Going Cheap
A sustainable competitive advantage can protect a company’s revenues and profits. We outline five stocks with an advantage not priced in by the market
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
11/06/2019PurchaseEmma N Walmsley1,584.807111.00
11/06/2019Transfer inEmma N Walmsley0.0070.00
10/05/2019PurchaseEmma N Walmsley1,511.689136.00
10/05/2019Transfer inEmma N Walmsley0.0090.00

Company Profile

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Sector

Drug Manufacturers - Major

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 24/07/2019

Half-Yearly Results
Ratios
Comp
More ...
PER (E)19.43
Div Yld (E)5.24
PEG (E)3.37
ROCE19.86
Op Mrgn0.23
EPS Grwth0.83
Dividends
PreviousLatest
More ...
Record Date22/02/1917/05/19
Ex-Div21/02/1916/05/19
Paid11/04/1911/07/19
Amnt23.0019.00
Directors
More ...
Non-Executive DirectorMs. Lynn Laverty Elsenhans
Executive Director, Chief Scientific Officer and President, RandDDr. Hal V Barron
Non-Executive DirectorMs. Judy C. Lewent
Non-Executive DirectorDr. Laurie H. Glimcher M.D.
Non-Executive DirectorMr. Manvinder Singh Banga
Non-Executive Director, ChairmanSir Philip Roy Hampton KB
Non-Executive DirectorMr. Urs Rohner
Non-Executive DirectorDr Vivienne Cox CBE
Company SecretaryMrs. Victoria Anne Whyte
Executive Director, Chief Financial OfficerMr. Iain J Mackay
Executive Director, Chief Executive OfficerEmma N Walmsley
Non-Executive DirectorDr. Jesse Goodman
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.